ZA200606458B - Analyte test system for determining the concentration of an analyte in a physiological fluid - Google Patents
Analyte test system for determining the concentration of an analyte in a physiological fluid Download PDFInfo
- Publication number
- ZA200606458B ZA200606458B ZA200606458A ZA200606458A ZA200606458B ZA 200606458 B ZA200606458 B ZA 200606458B ZA 200606458 A ZA200606458 A ZA 200606458A ZA 200606458 A ZA200606458 A ZA 200606458A ZA 200606458 B ZA200606458 B ZA 200606458B
- Authority
- ZA
- South Africa
- Prior art keywords
- analyte
- analyte test
- test element
- areas
- element according
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims description 227
- 238000012360 testing method Methods 0.000 title claims description 188
- 239000012530 fluid Substances 0.000 title claims description 59
- 239000000523 sample Substances 0.000 claims description 153
- 238000001514 detection method Methods 0.000 claims description 100
- 239000000203 mixture Substances 0.000 claims description 79
- 238000009472 formulation Methods 0.000 claims description 72
- 238000009826 distribution Methods 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 47
- 230000003197 catalytic effect Effects 0.000 claims description 41
- 230000002209 hydrophobic effect Effects 0.000 claims description 30
- 238000005259 measurement Methods 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000000758 substrate Substances 0.000 claims description 21
- 238000000576 coating method Methods 0.000 claims description 12
- 238000002835 absorbance Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- -1 polysiloxanes Polymers 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 230000005540 biological transmission Effects 0.000 claims description 5
- 238000005375 photometry Methods 0.000 claims description 5
- 229920001296 polysiloxane Polymers 0.000 claims description 5
- DXPPIEDUBFUSEZ-UHFFFAOYSA-N 6-methylheptyl prop-2-enoate Chemical class CC(C)CCCCCOC(=O)C=C DXPPIEDUBFUSEZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 238000001459 lithography Methods 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 235000012731 ponceau 4R Nutrition 0.000 claims description 4
- 238000001228 spectrum Methods 0.000 claims description 4
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 claims description 4
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims description 3
- 102100034866 Kallikrein-6 Human genes 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 150000001925 cycloalkenes Chemical class 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 3
- 238000007647 flexography Methods 0.000 claims description 3
- 229920000578 graft copolymer Polymers 0.000 claims description 3
- 238000010030 laminating Methods 0.000 claims description 3
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical class CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 claims description 3
- 229920001225 polyester resin Polymers 0.000 claims description 3
- 239000004645 polyester resin Substances 0.000 claims description 3
- 229940068917 polyethylene glycols Drugs 0.000 claims description 3
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 3
- 229920000098 polyolefin Polymers 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 238000004080 punching Methods 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- YSVBPNGJESBVRM-ZPZFBZIMSA-L Carmoisine Chemical compound [Na+].[Na+].C1=CC=C2C(/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)O)=CC=C(S([O-])(=O)=O)C2=C1 YSVBPNGJESBVRM-ZPZFBZIMSA-L 0.000 claims description 2
- 108020005199 Dehydrogenases Proteins 0.000 claims description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 108091007187 Reductases Proteins 0.000 claims description 2
- 102000004357 Transferases Human genes 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000004982 aromatic amines Chemical class 0.000 claims description 2
- 239000004176 azorubin Substances 0.000 claims description 2
- 235000012733 azorubine Nutrition 0.000 claims description 2
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical class C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 claims description 2
- 235000012709 brilliant black BN Nutrition 0.000 claims description 2
- 239000004126 brilliant black BN Substances 0.000 claims description 2
- 229940031019 carmoisine Drugs 0.000 claims description 2
- 238000004049 embossing Methods 0.000 claims description 2
- 238000005530 etching Methods 0.000 claims description 2
- 150000007857 hydrazones Chemical class 0.000 claims description 2
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 2
- 229960003988 indigo carmine Drugs 0.000 claims description 2
- 235000012738 indigotine Nutrition 0.000 claims description 2
- 239000004179 indigotine Substances 0.000 claims description 2
- 229940107698 malachite green Drugs 0.000 claims description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical class [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims description 2
- QLOAVXSYZAJECW-UHFFFAOYSA-N methane;molecular fluorine Chemical group C.FF QLOAVXSYZAJECW-UHFFFAOYSA-N 0.000 claims description 2
- 229940048276 new coccine Drugs 0.000 claims description 2
- 239000004175 ponceau 4R Substances 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 claims description 2
- 235000012756 tartrazine Nutrition 0.000 claims description 2
- 239000004149 tartrazine Substances 0.000 claims description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims description 2
- 229960000943 tartrazine Drugs 0.000 claims description 2
- GMMAPXRGRVJYJY-UHFFFAOYSA-J tetrasodium 4-acetamido-5-hydroxy-6-[[7-sulfonato-4-[(4-sulfonatophenyl)diazenyl]naphthalen-1-yl]diazenyl]naphthalene-1,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].OC1=C2C(NC(=O)C)=CC=C(S([O-])(=O)=O)C2=CC(S([O-])(=O)=O)=C1N=NC(C1=CC(=CC=C11)S([O-])(=O)=O)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 GMMAPXRGRVJYJY-UHFFFAOYSA-J 0.000 claims description 2
- MPCYPRXRVWZKGF-UHFFFAOYSA-J tetrasodium 5-amino-3-[[4-[4-[(8-amino-1-hydroxy-3,6-disulfonatonaphthalen-2-yl)diazenyl]phenyl]phenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N=NC3=CC=C(C=C3)C3=CC=C(C=C3)N=NC3=C(C=C4C=C(C=C(C4=C3O)N)S([O-])(=O)=O)S([O-])(=O)=O)=C(O)C2=C1N MPCYPRXRVWZKGF-UHFFFAOYSA-J 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims 3
- 238000005229 chemical vapour deposition Methods 0.000 claims 2
- 150000002433 hydrophilic molecules Chemical group 0.000 claims 2
- 238000005240 physical vapour deposition Methods 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920001534 polyethylene glycol copolymer Polymers 0.000 claims 1
- 239000010410 layer Substances 0.000 description 80
- 229960001031 glucose Drugs 0.000 description 25
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 22
- 239000000975 dye Substances 0.000 description 21
- 235000001727 glucose Nutrition 0.000 description 21
- 239000000976 ink Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 18
- 230000003287 optical effect Effects 0.000 description 18
- 230000037361 pathway Effects 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000007639 printing Methods 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000010200 validation analysis Methods 0.000 description 8
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000005660 hydrophilic surface Effects 0.000 description 4
- 230000005661 hydrophobic surface Effects 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003705 background correction Methods 0.000 description 3
- 229910052729 chemical element Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001723 curing Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 239000000174 gluconic acid Substances 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000000275 quality assurance Methods 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 2
- ZFRBZRZEKIOGQI-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1,3-disulfonic acid Chemical compound C1=CC(O)=C2C(N)=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 ZFRBZRZEKIOGQI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101100313377 Caenorhabditis elegans stip-1 gene Proteins 0.000 description 2
- 101100313382 Dictyostelium discoideum stip-2 gene Proteins 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241001399289 Propedies Species 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 101100516335 Rattus norvegicus Necab1 gene Proteins 0.000 description 2
- 101150059016 TFIP11 gene Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000004697 chelate complex Chemical class 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007641 inkjet printing Methods 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940044603 styrene Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 description 1
- RZVINYQDSSQUKO-UHFFFAOYSA-N 2-phenoxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC1=CC=CC=C1 RZVINYQDSSQUKO-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- LWKJNIMGNUTZOO-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzenesulfonic acid Chemical compound OC1=C(Cl)C=C(Cl)C=C1S(O)(=O)=O LWKJNIMGNUTZOO-UHFFFAOYSA-N 0.000 description 1
- GUATVOIAFCJUMM-UHFFFAOYSA-N 3-methyl-2-sulfonyl-1,3-benzothiazole 1-oxide Chemical compound C1=CC=C2S(=O)C(=S(=O)=O)N(C)C2=C1 GUATVOIAFCJUMM-UHFFFAOYSA-N 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- ATTTYDOGGQCDDK-UHFFFAOYSA-N C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 Chemical compound C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 ATTTYDOGGQCDDK-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 101150004367 Il4i1 gene Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001079660 Phanes Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000003848 UV Light-Curing Methods 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000009658 destructive testing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001227 electron beam curing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- OEZPVSPULCMUQB-VRTOBVRTSA-N hydron;(e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine;chloride Chemical compound Cl.C1=CC=C2S\C(=N\N)N(C)C2=C1 OEZPVSPULCMUQB-VRTOBVRTSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000013208 measuring procedure Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002365 multiple layer Substances 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCTAWXVAICEBSD-UHFFFAOYSA-N prop-2-enoyloxy prop-2-eneperoxoate Chemical compound C=CC(=O)OOOC(=O)C=C KCTAWXVAICEBSD-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- SDVOJIRXJLEGCY-ZFRLFKIJSA-N spc3 Chemical compound N([C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCCCC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCCNC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)CN)C(=O)NCCC(O)=O)C(=O)CNC(=O)[C@@H]1CCCN1C(=O)CN SDVOJIRXJLEGCY-ZFRLFKIJSA-N 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
Analyte Test System for Determining the Concentration of an Analyte in a Physiological Fluid
This invention relates to the field of quantitative analysis of an analyte, e. g. glucose, in a physiological fluid, e. g. blood. More particulady, this invention provides an analyte test system and test method for the quantitative determination of analytes in a physiological fluid and a method of preparation.
The determination of analyte concentrations in physiological samples plays a prominent role in diagnosis and therapy of a variety of diseases. Analytes of interest include among oth- ers glucose, cholesterol, free fatty acids, triglycerides, proteins, ketones, phenylalanine, en- zymes, antibodies, ot peptides in blood, plasma, urine or saliva.
Typically, a physiological sample fluid, e. g. capillary blood, is applied to a test strip to evaluate the concentration of an analyte. The test strips are usually used in conjunction with a measuring device which measures some electrical properties, such as electrical current, if the strip is designed for detection of an electro-active compound, or for the measurement of light reflectance and/or transmittance, if the stip is designed for photometric detection. In sys- tems with optical detection technology a mixtute of enzymes and colour-generating materials known as chromogens is located on the test strip. The analyte contained in the physiological fluid, which has been applied to the test strip, reacts with the reagents and causes a change in reflectance or transmittance thereby indicating the concentration of the analyte in the test sample.
For example, glucose is determined quantitatively by oxidizing glucose with glucose oxidase to gluconic acid. The reaction product hydrogen peroxide causes in conjunction with a peroxidase, such as horseradish peroxidase, the conversion of a substrate, i. e. an indicator, into a chromogenic product, which is detectable and relates proportional to the glucose con- centration in the sample fluid.
Measuring the glucose concentration in samples of whole blood is a particularly common task. Since Diabetes causes dangerous physiological complications leading to the loss of vision, kidney failure and other serious medical consequences. Only a stringent therapy and disease management minimises the tisk of these consequences with adjustments on exer- cise, diet; and medication. Some patients have to test their blood glucose concentration fre- quently with four or more measurements a day. These patients as well as clinicians and hospi- tals require an accurate, reliable, and ideally inexpensive method to adjust their treatment re- gimes.to avoid the long-term complications of diabetes mellitus.
The increased awareness about diabetes, the acceptance of self-monitoring and self- treatment have been dependent upon the availability of suitable devices and let to the devel opment of a multitude of devices and methods for personal use and point of care testing as well. Available are pregnancy, ovulations, blood coagulation, ketone and cholesterol tests, as example for a non-exhaustive selection, but most prominent in the area of self-monitoring is still the detection of glucose in capillary blood. :
An exemplary device for monitoring the concentration of an analyte, e. g. glucose, in blood is disclosed in the US Patent 4,935,346. The method involves taking a reflectance read- ing from the surface of an inert porous matrix impregnated with a reagent that will interact with the analyte to produce a light-absorbing reaction product. Most of the devices of the prior art are designed to have one measurement area or measurement chamber in which the test sample is introduced directly or via a fluidic path or channel, the test chamber or test membrane contains all materials necessary for the reactions, which produce a detectable col- out change of the sample fluid.
US Patent 5,430,542 discloses a disposable optical cuvette and method of manufactur- ing. The cuvette comprises two optically transparent liquid impermeable plastic sheets. A :
third adhesive sheet is positioned between the two transparent plastic sheets and all three sheets are pressed and sealed together.
US Patent 5,268,146 discloses a qualitative test panel for testing 2 sample for the pres- ence of an analyte containing all reagents and components necessary to achieve a visible indi- cation of the presence or absence of an analyte in the sample.
US Patents 4,761,381 and 5,997,817 disclose devices wherein the liquid samples to be analysed are applied to sample application ports which give the liquid entry to capillary chan- - nels leading to reaction chambers which contain material capable of detecting the compo- nents of interest in the liquids.
US Patent Application Publications. US 2002/0110486A1 and US 2003/0031594 A1l disclose fluidic medical diagnostic devices permitting the measurement of analyte concentra- tion or a property of a biological fluid, particularly the coagulation time of blood, the devices having at one end a sample port for introducing a sample and at the other end a bladder for drawing the sample via a channel to a measurement ares, in which a physical parameter of the sample is measured and related to the analyte concentration or property of the fluid.
Due to raw material and process variations in large-scale manufacture of these strips an adequate strip-to-strip reproducibility from one batch to the next is not guaranteed. There- fore, it is necessary to assign a calibration code to each lot of strips that corrects for this vari- ability. The calibration code may be marked on the strip container, and the user must enter the code into the meter when a new batch of strips is used. If the user fails to enter a new calibration code or enters an incorrect one, the resulting measurement will be incorrect. Some prior art strips, e. g. the strip disclosed in US 6,168,957B1, are designed to incorporate the calibration code on the strip, thus the meter can read the calibration code before calculating the glucose concentration. The disposable nature of single use diagnostic strips allow only destructive testing, due to the consumption of reagents during the determination step, and thus permit only a statistical evaluation of the batch petformance by the manufacturer, which does not give 100% certainty of the performance of an individual test strip.
More importantly, these types of calibradon codes convey only retrospective informa- tion to the analytical strip-reading device or meter. Thus, a meter cannot assess the true his- tory of a particular reagent test strip, e. g. incorrect storage conditions or faulty packaging, and will generate an error message only if the strip provides completely erroneous and off scale readings in comparison to the pre-program data ot validation methods.
The user can only check and proof the accuracy and functionality of a reagent test strip with specially prepared control solutions of known concentrations provided by the manufac- turer. Nevertheless, this method is also disadvantageous, since the quality check leads to in- creased strip consumption and therefore to increased costs. Likewise, this method does not take into consideration the quality variations within 2 batch. :
Some of the devices of the prior art have integrated positive and/or negative controls, which ate activated by the addition of the sample. For instance, in the above mentioned US
Patent 5,268,146 preferred embodiments of the test device include a built-in positive control and/or a built-in negative control which consist of further measuring areas containing re- agents which will either induce the visible change in the indicator by themselves or prevent the change from occurring independently of the presence or absence of the analyte in the test sample. Also, the test device of the US Patent 4,578,358 for detecting the presence of occult blood in bodily substances includes positive and negative control areas.
An integrated positive or negative control as disclosed in the above two patents and known commonly from pregnancy tests provides only useful information in conjunction with qualitative and threshold test panels or strips indicating the presence or absence of an analyte but is meaningless for the quality assurance of quantitative determination of analytes such as glucose in whole blood.
Furthermore, the measuring procedure may be impaired by other variable factors in the physiological sample fluid. A typical complication in whole blood analysis is the variability of erythrocyte levels, leading to results which may not reflect the real analyte concentration of the sample.
In view of the aforementioned shortcomings, it is the object of the present invention to provide a device which bas an integrated calibration system, which accounts for and compen- sates any variability may it be generated by fluctuations in the production process or by the vatiability of the analysed sample itself to assure the user that the test has been propedy per- formed and the result is accurate and reliable.
So far, no dry reagent test strip with integrated calibration system has been disclosed by prior art, but a variety of prior art publications describes test strips with pluralities of reac- tions zones used to detect a plurality of analytes of to integrate positive or negative controls as indicated above.
A particular interesting prior art test strip comprising 2 plurality of reaction zones util- ised for quality assurance purposes but not for a strip internal calibration procedure has been disclosed in US Patent Application Publications US 2002/0110486A1 and US 2003/0031594
Al. The test sttip requires a volume of about 20uL blood and is used to determine the 5 ptothrombin time, an important parameter to characterise blood coagulation. However, if a user has to test several times a day, as required for proper management of diabetes mellitus, these large sample volumes ate unpractical and disadvantageous especially in comparison with the state of the art blood glucose systems which require only sbout 1ul. of whole blood but require in all events a patient performed calibration procedure as well. -
A reduction of the volume of the channels and cavities forming the measuring cavities in the described stip would require complex and expensive production procedutes, such as “micro-moulding”, which are less suitable for large-scale production of inexpensive and dis- posable sensors.
Accordingly, it is a further object of the present invention to provide an analyte test system for dry reagent test strips, which requires not only small volumes of physiological fluid but also a production process which does not involve many and complicated production steps and therefore is inexpensive and usable for products assisting patients in self- monitoring blood glucose or other important physiological parameters.
Summary of the invention ‘This invention provides a device for determining the concentration of an analyte like glucose, cholesterol, free fatty acids, triglycerides, proteins, ketones, phenylalanine or en- zymes, in a physiological fluid like blood, serum, plasma, saliva, urine, interstitial and/or in- tracellular fluid, the device having an integrated calibration and quality control system suitable for dry reagent test strips with a very small sample volume of about 0.5uL based on to a new sample distribution system. The production of the inventive analyte test element involves only a small number of uncomplicated production steps enabling an inexpensive production of the strips.
Due to the integrated calibration procedure the analyte test system of the present inven- tion provides reliable results regardless of the blood type, haematocrit level, temperature etc.
In addition, production variations are compensated by the integrated calibration procedure as well. Moreover, active component aging is now detectable and can be compensated and/or reported which will lead to a prolonged shelf live of the product under suitable storage condi- tions. :
The present invention provides an analyte test element for determining the concentra- tion of at least one analyte in a physiological sample fluid having a first and a second surface in a predetermined distance opposite from each other, said both sutfaces ate provided with : two substantially equivalent patterns forming areas of high and low surface energy which are aligned mostly congruent to create a sample distribution system with at least two detection areas, wherein the applied physiological fluid is constrained to the areas with high surface energy.
The sample distribution system contained in the inner part of the analyte test element has no mechanical and/or structural features resembling walls, groves, or channels to handle and manipulate the physiological fluid or other aqueous sample fluids. The analyte test ele- ment is described in several embodiments suitable for a variety of calibration procedures and adaptable to different analytes and chemical determination methods; it is easily integrated in test strips used for a single measurement or in mote complex armngements such as analyte test disks or bandoliers to provide base units for several measurements.
In a preferred embodiment, the analyte test element provides » predetermined detection areas of said first sutface coated with a catalytic formulation promoting the detection of an analyte in a physiological fluid, and » predetermined detection areas of said second surface coated with # calibration for- mulations made up of m blank formulations and sn formulations with different levels of calibration compound, whereby 7 is an integer number larger than 2, is an integer number equal or larger than 1, and # >m, configured proximal to the centre of the analyte test clement, enabling the detection means to obtain # results from 2s predetermined detection areas and subsequently allowing a processing means to calculate #-m calibration coefficients of 2 polynomial calibration equation obeying 7 = Been), 1 one regression coefficient to validate the quality of the calculated 7 calibration coefficients "of the calibration equation, and the determination of the unknown conceatration of an ana-
Iyte in 2 physiological fluid sample.
In another aspect, the invention provides a method for preparing the analyte test ele- ment of the present invention with the steps: generating areas of high and low surface energy on a base layer having a first surface, the areas of high surface energy forming a hydrophilic pathway with # predetermined detec- tion areas, whereby # is an integer number larger than 2, generating a corresponding pattern of areas of high and low surface energy on a cover layer having a second surface, coating a catalytic formulation on the # detection areas of the first surface, said catalytic formulation promoting the detection of an analyte concentration contained in a physiological fluid sample using transmission or absorbance photometry, : coating # calibration formulations on # detection areas of the second surface, said # ca- libration formulations made up of m blank formulations and »-m formulations with different levels of calibration compound, whereby a is an integer number of at least 1, and a>m, which is identical ot substantially equivalent to the analyte and able to induce the same che- mical reaction in the catalytic formulation as the analyte in the physiological fluid sample, laminating the layers of first and second surfaces to the opposite sites of a centre layer having a discontinuity which provides a cavity for the sample distribution system formed by the areas of high surface energy on the first and second surfaces of the base and cover layer, punching or cutting the laminated sheets to the final shape.
Other features and advantages of the present invention and the preferred embodiment thereof will become apparent from the following description in conjunction with the attached
Fig1 is a perspective view of one embodiment of the analyte test element of the pre- seat invention provided in shape of a test strip.
Fig. 2 is a perspective view of the embodiment according to Fig. 1, showing the sample distribution system enlarged.
Fig. 3 is an exploded perspective view of the device according to Fig. 1 showing the three layers separately.
Fig. 4 shows different forms of the discontinuity of the centre layer forming the sample cavity together with the first and second surface.
Fig. 5 is a sectional view of a detection area of the sample distribution system con- structed by hydrophobic guiding elements.
Fig. 6 is a sectional view of another embodiment of a detection area of the sample dis tribution system using hydrophilic pathways.
Fig. 7 shows different embodiments of the sample distribution system with different patterns of pathways and detection areas suitable for different calibration methods.
Fig. 8 shows the sample distribution system of Fig. 6 in conjunction with a light emitter and detector means in a sectional view.
Fig. 9 is a graph showing the calculation of the sample analyte concentration using the standard addition method.
Fig. 10 is a graph showing the validation method for the calculated result and calibra- tion data. :
Fig. 11 shows different shapes of the analyte test strip.
Fig. 12 shows an exemplary application of an inventive test strip with a meter.
Fig. 13 shows the analyte test system with an inserted analyte test strip.
Fig. 14 shows the construction of an analyte test disk.
Fig. 15 shows an analyte test disk compared to an analyte test strip.
Fig, 16 shows a analyte test system with an integrated analyte test disk.
Fig. 17 shows a analyte test system with an analyte test strip in left hand and right hand handling mode.
Fig. 18 shows an analyte test bandolier and folded bandolier to build a stack.
Fig, 19 shows the production steps of the analyte test elements with strip shape.
The layers shown in Fig. 5, 6, and 8 are not to scale, in particular the thickness of the layers 16, 17, 18, 19 are largely exaggerated.
As shown in Fig. 1 and Fig. 2, the analyte test strip 1 of the present invention is 2 mul- tiple layer arrangement comprising a base layer 2, a centre layer 3 ovedaying the base layer 2, and a cover layer 4 overlaying the centre layer 3. The centre layer 3 presents a discontinuity 5, which creates a hollow cavity in conjunction with the base layer 2 and the cover layer 4. . Within said cavity there is located a sample distribution system 6 which is connected to 2 sample application area 9 located on one side of the analyte test strip. The sample application
_ area 9 as interface to the user is preferably formed by a convex curve 10 extending from one major side of the analyte test strip for easier application of the sample. Opposite to the sam- ple application area 9, 10 on the second major side of the analyte test strip is the location of an air vent 11 allowing the displacement of air while the physiological fluid is distributed to the predetermined detection areas 6a, 6a (see Fig. 3). It might be noted that the construction requires only one air vent independent of the amount of predetermined detection areas used within the analyte test element. The described elements of the sample distribution system with areas of high surface energy, sample application area, air vent, centre layer and disconti- nuity in the centre layer form the totality of the analyte test element, which creates the intrin- sic capillary action to exert the distribution of the applied physiological fluid to the predeter- mined detection areas.
In addition, the analyte test strip 1 possesses registration features 7, 8 useful to differen- tiate between several kinds of analyte test strips for the determination of different analytes. By this means, a multi-analyte meter could be instructed to run a special program or procedures with selectable parameters upon strip insertion required for the determination of a particular analyte. As illustrated in Fig. 3, which represents the multi-layer arrangement of Fig. 1 and 2 in an exploded view, the base layer 2 provides a first surface 2a, and the cover layer 4 provides a second surface 4a. The first surface 2a and the second surface 4a are patterned with areas which will create the sample distribution system 6. The pattern of the sample distribution system 6 comprises a predetermined number of analyte detection areas 6a and sample path- ways 6b, which are aligned and registered mostly congruent upon assembly of the multi-layer arrangement. The centre layer 3 defines the distance between the first surface 2a of the base layer 2 and the second surface 4a of the cover layer 4 and has a discontinuity 5 to form a hol- low cavity together with the first surface 2a of the base layer 2 and the second surface 4a of the cover layer 4. The sample distribution system 6 which will be formed between the first surface 2a and second surface 4a is located within the cavity created by the discontinuity 5 of the centre layer 3 and the first surface 2a of the base layer 2 and the second surface 4a of the cover layer 4. Preferably, the hollow cavity is substantially latger by design than the sample distdbution system.
Since the purpose of the discontinuity 5 of the centre layer is only to create a cavity for the sample distribution system 6, the discontinuity 5 of the centre layer 3 can have different forms, examples thereof are shown in Fig. 4. Fig. 4a shows an umbrella shaped analyte test element cavity 12, Fig. 4b shows a rectangular analyte test element cavity 13, and in Fig. 4c the sample cavity 14 has a circular shape. The discontinuity 5 of the centre layer 3 does not influence the size of the predetermined detection areas 6a and the size of the pathways 6b of the sample distribution system 6 and therefore does not influence or change the required sample volume. Compared to the sample distribution system 6, the cavity shapes shown in
Fig. 4 are rather simple, thus allowing the application of simple punch tools and fast process- ing with less demand on the registration accuracy.
The sample distribution system 6 located in the cavity formed by the discontinuity 5 of the centre layer 3 and the first surface 2a of the base layer 2 and the second surface 4a of the cover layer 4 is formed by creating areas of high and low surface energy on said surfaces 2a and 4a. The areas of high and low surface energy on the first surface 2a of the base layer 2 and the second surface 4a of the cover layer 4 are aligned and registered mostly congruent to each other. Since the applied physiological fluid or any other aqueous sample is wetting only the areas with high surface enetgy, it is thus constrained within the predetermined flow paths 6b and detection areas 6a of the sample distribution system 6 and between the first surface 2a of the base layer 2 and the second sutface 4a of the cover layer 4.
Fig. 5 shows a construction of the sample disttibution system 6 using hydrophobic “guiding elements ”. In this embodiment of the analyte test element of the present invention the base layer 2 and the cover layer 4 are coated with a hydrophobic layer 16, except the areas, which will form the sample pathways and detection areas. The hydrophobic layer 16 creates an area with low surface energy, which will exert a repellent force onto an applied sample fluid and constrain the sample fluid therefore to the areas of high surface energy which will form the sample distribution system.
Preferably, the hydrophobic layer 16 is applied on a hydrophilic surface, which is wet- table by the physiological fluid and transparent for light, particular in the UV, near IR, and/or visible range of the electromagnetic spectrum. The procedure described above requires a hydrophilic surface, which can be produced from a natural hydrophilic polymer such as cello- phane or glass as well as from a hydrophobic surfaces of common polymers (examples are given below) by rendering the hydrophobic surface hydrophilic using a coating process or physical or chemical plasma deposition of hydrophilic monomers that can be vaporised in vacuum, e. g. ethylene oxide, ethylene glycol, pyrrole or acrylic acid. Subsequently, the pattern of “guiding elements” can be realized by printing hydrophobic ink on the hydrophilic surfaces of the base and cover layers. - A suitable hydrophobic ink will have contact angels with water of typically more than 70° and a surface enetgy of typically less than 33 mN/m and contain monomers, oligomers, and pre-polymets with hydrophobic functions, like isooctyl acrylates, dodecyl acrylates, sty- rene derivates, or systems with partly fluotinated carbon chains.
Fig. 6 shows another construction of the sample distribution system using hydrophilic pathways. In this embodiment of the analyte test element the base layer 2 and the cover layer 4 are coated with a hydrophilic layer 17 thereby creating areas of high surface energy.
The hydrophilic agent printed on the hydrophobic surface is highly wettable by a physiological fluid; thus, the areas of high surface energy creating the hydrophilic pathways of the sample distribution system will exert a positive capillary force onto the applied physiologi- cal sample fluid to transport the sample fluid to the separate detection areas.
The hydrophilic pattern can be realized by printing a cross-linkable and/or partly in- soluble hydrophilic of amphiphilic agent on 2 hydrophobic surface. Inks with hydrophilic functions can be realised from a wide selection of cross-linkable water-soluble polymers, par- ticularly useful are acrylate derivatives prepared form polyalcohols, polyethylene-glycols, poly- . ethylene-oxides, vinylpyrolidone, alkyl-phosphocholine derivates and others; particularly use- ful are also organo-modified silicone actylates, which are a cross-linkable species of organo- modified polysiloxanes. Suitable coatings provide a contact angle with water of typically less than 25° and a surface energy of typically more than 70 mN/m.
The base layer 2 and cover layer 4 suitable as substrate for the printing process may be formed of a material like glass, polyvinyl acetate, poly-methyl-methacrylate, poly-dimethyl- siloxane, polyesters and polyester resins containing fluorene rings, polycarbonates and poly- carbonate-polystyrene graft copolymers, terminal modified polycarbonates, polyolefins, cycloolefins and cycloolefin copolymers, and/or olefin-maleimide copolymers.
In case the substrate has an intermediate hydrophobic character, the printing of hydro- philic pathways with a surrounding hydrophobic pattern, i. e., a combination of the construc- tions of Fig. 5 and Fig. 6, is possible as well.
In an alternative embodiment only one of the first and second surface is provided with the hydrophilic/hydrophobic patterns to create the sample distribution system. However, preferably both the first and the second surface are provided with equivalent patterns of high and low sutface energy to ensure a proper distribution of the sample fluid within the hydro- philic pathways of the sample distribution system.
Moteoves, it is possible to physically elevate the areas of high sutface energy of first and second surfaces from the areas of low surface energy by etching or embossing. ~The volume requirement for the sample distribution system contained in the analyte test element of the preferred embodiment is with about 0.5uL-1.0pL very low and requires only about 100nL — 150nL per detection area, whether the areas of high aad low surface energy ate created by hydrophobic guiding elements or hydrophilic pathways or by a combi- nation of both. However, it will be obvious for the one skilled in the art that the volume of the sample distribution system will vary with various designs and with the number of em- ployed predetermined detection areas.
As stated above, the creation of a sample distribution system with such volume includ- ing a plumlity of sample distribution pathways and detection areas is very difficult or even impossible with prior art test strip technology. The amount of physiological sample needed for a measurement in the analyte test element of the present invention is e. g. as low as 1/40 part of the amount which is required for the operation of the device disclosed by Shartel et al in US Patent Application Publications US 2002/0110486A1 and US 2003/0031594 Al and e. g- 1/10 of the volume of prior art micro-cuvettes (HemoCue Glucose Systems).
Fig. 7 shows different patterns of the sample distribution system, which can be realized by hydrophilic pathways as illustrated in Fig. 6, or by the hydrophobic “guiding elements” as illustrated in Fig. 5, or by a combination of hydrophilic pathways and hydrophobic guiding elements. Cell Al in Fig. 7 illustrates all cases for the simplest sample distribution system.
Column A of Fig. 7 shows the formal design of sample distribution systems with no back- ground correction, whereas column B provides designs for sample distribution systems with background corrections, column C indicates the highest order of the polynomial calibration equation achievable with the adjacent designs, and column # indicates the required number of predetermined detection aress of each surface, respectively the number of required measure- ments. The literals in each design indicate the position of the background correction (c), sam- ple (1), and all associated calibration areas (2, 3, 4, 5, 6) with increasing amount of calibration compound. The simplest calibration is represented by a linear equation where the relation- ship between measurement and the analyte concentration is strictly proportional. The calibsa- tion of the analyte test element is generally performed using the standard addition method by adding the calibration compound of the different calibration areas to the sample and subse- quent calculation of a linear or monotone non-linear calibration equation. Fig. 9 gives a more detailed explanation about case I. The calibration model or order (column C) needs to be appropriate for the selected analyte and employed detection chemistry, consequently it is not possible to apply a linear calibration model to a chemical reaction which obeys a fourth order model and vice versa. However, it is still possible to use the analyte test element designed for five standard additions for a linear calibration, the higher amount of standards will allow an even more precise measurement and a statistical validation with higher significance in terms of correlation coefficient, standard deviation and standard error of the test compared to a linear calibration based on two standards.
Moreovet, the repetition of sample and standard measurements is possible as well, thus it is possible to petform two independent linear calibrations for one particular sample of phy- siological fluid with the embodiments shown in row IV. Likewise, it is possible to use the same analyte test element for the determination of two analytes.
On the contrary, a multi analyte system can be realised within the same set of prede- termined detection areas if the selected detection chemistries generates no interference prob- lems, thus the reaction educts and products of one reaction will not take part in the other reaction and the produced indicator dye absorbs the light in a substantially different wave length range.
Referring to Fig. 3, the analyte detection areas 6’a of the sample distribution system 6 of the first surface 2a of the base layer 2 are characterized in that they are coated with a cata- lytic formulation 18, as shown in Figures 5 and 6. The catalytic formulation 18 contains as reactive components a promoter undetgoing a catalytic or non-catalytic reaction with the ana- lyte, if necessary, in conjunction with a co-enzyme, and an indicator generating an optically detectable product, thus allowing the detection of the analyte contained in sample 15 by transmission or absorbance photometry. : Preferably, the promoter is an enzyme selected from the group consisting of dehydro- genases, kinases, oxidases, phosphatases, reductases and/or transferases. The optional co- enzyme contained in the catalytic formulation is a substance required by certain enzymes to facilitate the enzymatic reaction, 3-nicotineamide adenine dinucleotide is required for example by glucose dehydrogenase.
In one assay system for determining concentration of glucose, glucose in the sample is oxidized by oxygen and glucose oxidase to form gluconic acid and H,O,. The amount of
H,0, produced is then measured quantitatively by Reaction (1) or Reaction (2).
Reaction (1):
POD
Dye (coloutless) + H,0, —————=> Oridized dye (coloured) + HO
Reaction (2):
HO, + Fe > Fe* + HO
Fe* + dye > Fe** dye complex
In Reaction (1), the enzyme peroxidase (e. g., horseradish peroxidase, microperoxidase) _ catalyzes the oxidation of the dye and converts H,O, to H;O. The colour intensity is directdy proportional to the concentration of glucose in the sample. Representative examples of dyes include o-dianisidine, 4-aminocantipyrine, and 3,3',5,5 -tetamethybenzidine. In Reaction (2),
H,0, oxidizes the Fe** to Fe*. Fe*" forms a coloured chelate complex with a specific absorp- tion peak. Representative examples of ferrous salt include ferrous sulfate and potassium fertocyanide. Representative examples of the chelate-dye include xylenol orange. The amount of formed Fe** chelate complex is proportional to the amount of glucose in the sample.
In another assay used to determine ghicose concentrations in physiological fluids is shown in Reaction (3); here glucose dehydrogenase (GDH) reacts specifically with ghicose in the sample in presence of a co-enzyme (3-nicotinamide adenine dinucleotide (3-NAD)) to form NADH, the reduced form of 3-NAD. The NADH reacts subsequently with an electron accepting dye, e. g., 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), catalyzed by the diaphorsse enzyme to form a dark purple-reddish colour. The colour intensity measured at 640 nm is directly proportional to the concentration of ghicose in the sample.
Reaction (3):
GDH
Glucose + 3-NAD —————crceeoee- 2 Gluconic acid + NADH
Diaphorase
NADH + MTT (yellow) —-~---s--r---- => MIT (purple-reddish) + 3-NAD
An alternative strain to wild-type GDH is glucose dehydrogenase pyrroloquinolin- equinone (GDH-PQQ) which is often used for electrochemical blood glucose determination but could be employed in an optical detection method using indicator dyes formed by reduc- tion similar to the MTT ot by chelate complexes indicators as shown in the later half of reac- tion scheme (2).
Though, the catalytic formulation 18 may contin ghucose oxidase or glucose dehy- drogenase if the device is intended for the determination of glucose concentration in a physiological fluid.
Accordingly, the enzyme contained in the catalytic formulation may be cholesterol oxidase, where the analyte is cholesterol; alcohol oxidase, where the analyte is alcohol; lactate oxidase, where the analyte is lactate, and the like.
Indicators suitable to generate an optically detectable product by itself or in combina- tion with another chemical compounds and in conjunction with a suitable promoter, e. g. an enzyme, are preferably selected from the group consisting of aromatic amines, aromatic alco- hols, azines, benzidines, hydmzones, aminoantipyrines, conjugated amines, conjugated alco- hols, and aromatic and aliphatic aldehydes. Specific examples of the indicator include 3- methyl-2-benzothiazolinone hydrazone hydrochloride; 3-methyl-2-(sulfonyl)-benzothiazolone hydrazone hydrochloride (MBTH); 8-amino-l-napthol-5,7-disulfonic acid (Chicago acid); 3,355 -Tetramethylbenzidine (TMB); 4,5-dihydtoxy-2,7-napthalene-disulfonic acid; 1- hydroxy-2-naphthalene-sulfonic acid; ~N,N-dimethyl-aniline; o-tolidine; 3-dimethyl- aminobenzoic acid (DMAB); 2,2 -Azino-bis(3-ethylbenzothiszoline-6-sulfonic acid) diammo- nium salt (ABTS); 3-[4,5-dimethylthiazol-2-yl}-2,5-diphenyltetrazolium bromide (MTT); and/or 3,5-dichloro-2-hydroxybenzene-sulfonic acid. In case the chemical compound is an acid, a water-soluble salt of the acid, e. g. an ammonium salt, may be used in the preparation of the catalytic formulation.
A vatiety of enzyme inks suitable as catalytic formulation is avail- able from prior art publications e. g. Wong et al. (US Patent 6,312,888), Philips et al. (US Pat- eat 4,935,346), and Berti et al. (US Patent 4,247,297). Suitable catalytic formulations for the present invention ate based on a non-reactive base, indicator components (dyes), and an en- zyme or enzyme combinations as promoter. The non-reactive base provides a carrier, which needs to be suitable for the coating process, prefembly ink jet printing, enzyme stabilisation, and fixation of the enzyme and indicator system to the surface of the detection areas. An ex- emplary composition for 100 mL formulation is given below.
Non-reactive base:
Distilled water 65 ml
Citric acid 24g Buffer system
Sodium citrate . 2H,0 32g Buffer system
Polyethylene glycole 10g Crust inhibitor
N-Methylpyrolidone 20g Co-solvent for some indicator dyes (optional)
BAS . 30g Enzyme stabilization
Gafquat 440 (ISP) 1.0 mL Film forming agent :
Advantage S (ISP) 10g Film forming agent
PVA (low mol. weight) 15g Enzyme stabilization
Adjust pH to 6.5 and fill up to 100 mL
Catalytic formulation: (all components are added to 100 mL non-reactive base)
GOD (Aspergillus niger) 2.0 g (250 U/mL)
POD (Horseradish) 2.0 g (250 U/mL)
Indicator system a) TMB 0.801 g
Indicator system b) ABTS 0915¢
Indicator system c) MBTH 0.719 g
DMBA 0.551 g
Indicator system d) MBTH 0.359¢
Chicago acid 1.064 g
The catalytic formulation can be composed with the indicator systems a) to d) in combination with a vatiety of hydrogen peroxide producing enzymes such as
GOD. Albeit, the pH of the non-reactive base formulation needs to be adjusted to the re- quitements of a new enzyme if GOD is replaced by another catalyst.
Examples for non-enzyme catalysed reactions are the detection of albumin with tetrabromphenol blue and the detection of ketones with a phosphate buffered mixture of glycine and nitroprusside in the visible range of the electromagnetic spectrum.
If the analyte test element is designed to perform # determinations, whereby # is an integer number larger than 2, all of the » detection areas 6’a on the first surface are coated with the catalytic formulation 18 promoting the detection of the analyte in the physiologic sample. . Referring again to Fig. 3, 5 and 6, the detection areas 6a of the second surface 4a of the cover layer 4 are characterized in that they are coated with a calibration formulation 19 com- prising a calibration compound.
Preferably, the calibration compound contained in the calibration formulation 19 coa- ted on the predetermined detection areas 6a of second surface 4a is identical or substantially equivalent to the analyte and able to induce the same chemical reaction in the catalytic for- mulation as the analyte in the physiological fluid sample. In case the analyte of interest in the physiological sample is glucose then the calibration compound is preferably glucose as well.
The non-reactive base as described for the catalytic formulation is suitable for the calibration formulation as well and requires only the addition of the required levels of calibra- tion compound. N-Methylpyrolidone, a co-solvent required for some of the indicator dyes, can be omitted.
An exact dosing of the calibration compound applied to the different detection areas is critical for a proper calibration procedure and thus for a reliable calculation of the analyte concentration in the sample fluid. Therefore, as the catalytic formulation, also the calibration formulation is preferably coated on the predetermined detection areas by ink jet printing. By that means it is possible to dose exactly the amount of the calibration compound and to apply it on a specific detection area.
If the analyte test element is designed to perform # determinations, whereby # is an in- teger number larger than 2, then # predetermined detection areas on the second surface 4a are coated with the # calibration formulations made up of #-» formulations with different levels of calibration compound or analyte and s blank formulations, whereby # is an integer num- ber of at least 1, and #> . In other words, at least one of the # detection areas of the sample distribution system does not contain the calibration compound.
After the physiological fluid is applied to the sample application area and distributed to the predetermined detection areas by capillary action, it dissolves the catalytic formulations on the # predetermined detection areas of the first surface 2a as well as the # calibration for- mulations on the » predetermined detection areas of the second surface 4a forming a mixture of analyte, calibration compound (which may be additional analyte), promoter and indicator dye. Within these » mixtures the optical density is changing proportional to the different lev- els of calibmation compound plus the unknown level of analyte, thus allowing the optical de- termination of # results by transmission and/or absorbance photometry and the calculation of the analyte concentration. Preferably, the catalytic formulation and the calibration formula- tions applied to the predetermined detection areas are readily soluble by a physiological fluid and/or water and positioned close to each other to allow rapid diffusive mixing of both com- ponents, thus enabling a fast reaction of all components contained in the detection areas to expedite a fast photometric determination of the analyte concentration.
Fig. 8 shows a detector arrangement for measuring the optical density of the sample within the analyte test element according to Fig. 6. The arrangement includes a light source 20, which emits light 24 of a certain wave-length in ditection of the sample detection area.
The light emitted from the light source 20 passes through an optical arrangement 21, e. g. diffuser or lens, and an aperture 22, the base layer 2, the sample 15, and the cover layer 4 of the detection area and is detected on the opposite side of the device by a detector means 23.
Since there are more than two detection areas arranged within the sample disttibution system, whereby at least two of the detection areas contain known but different levels of cali- bration compound it is possible for the processing means to calculate the unknown concen- tration of the analyte from the # measurements performed with the physiological fluid in the analyte test element.
Fig. 9 shows an exemplary calculation of an analyte concentration in a sample by the linear standard addition method, 2 known calibration technique used in various fields of ana- lytical chemistry, but now integrated and used with a dry reagent test strip for the first time.
In this example, the sample distribution system includes three analyte detection areas, two are : coated with different predetermined levels of a calibration compound. After applying the physiological fluid to the sample distribution system, the catalytic reaction takes place in the analyte detection areas, and the light emitter and detection arrangement of the meter meas- ures a first optical absorbance 25a of the sample located in the detection area with the first - level of calibration compound. The readout of this detection area represents a signal propor- tional to the combined concentration of the first calibration compound and the concentration of the analyte. In parallel, a second optical absorbance 26a is measured of the sample located in the detection ares with the second level of calibration compound representing a signal pro- portional to the combined concentration of the second calibration compound and the con- centration of the analyte. Furthermore, a third optical absorbance 27a is determined of the detection area containing only the sample with unknown analyte concentration.
Since there is a linear correlation between optical deasity and concentration of the analyte, following Lambert-Beet’s Law, the processing means of the analyte test system can calculate by linear regression analysis of the measurements the coefficients for the calibration equation y=cy+c,x in the example above. The concentration of the analyte in physiological fluid sample is determined by the zero point (y=0) 28 of the previously calculated calibration equation,
A general representation of applicable calibration equations is given in form of: y= 5 {Cant™) with y =f(results of the optical measurement); x=f(concentration of the calibration com- pounds); # number of measurements.
This polynomial equation format provides in conjunction with the #-values presented in Fig. 7 the entity of most useful calibration models for the various designs of the sample distnbution systems in the aforementioned figure. The values for y and x may represent data calculated by a function to allow pre-processing of raw data generated by the detection mean.
Thus, it is possible to use a logarithmic function for linearisation of raw data.
It should be obvious from the discussion that the invention is not limited to the de- signs of sample distribution systems in Fig. 7; and someone skilled in the art becomes able to design a systems with # larger than 6 in conjunction with the provided information.
A detailed introduction in linear and non-linear standard addition methodology is given by Frank et al. (Anal. Chem., Vol. 50, No. 9, August 1978) and Saxberg et al. (Anal.
Chem. Vol 51, No 7, June 1979).
A preferred embodiment of the analyte test element of the present invention accord- ing to Fig. 3 is designed to comptise one detection area, which includes the catalytic com- pounds but no calibration compound (6a, and 6’a,, resp.), one detection area which includes the catalytic compounds and a first concentration of the calibration compound (6a, and 6’a,, resp.), one detection area which includes the catalytic compounds and a second concentration of the calibration compound (6a, and 6’a,, resp.) and one detection area for the background absorption (6c and 6’c, resp.). By means of the latter detection area, which includes neither a calibration compound nor catalytic compounds, it is possible to determine the background absorption of the sample and to consider it during the calibration process.
Fig, 10 illustrates a pre-programmed validation method for calculated results and cali- bration data, whereby the validity of the measured results is verified by defining a “validation window” 29 for valid and correct measurements. By this means, the analyte test system can constrain all data to a validated and useful concentration range, e. g. 30 to 600 mg/dL glu- cose, and a valid range for the optical density, e. g. 0.1 to 0.9. Likewise, the processing means can constrain the slope and the intercept or more general the coefficients c, to c,., to a valid range, which is particularly useful for non-linear polynomial equations. A population of valid measurements with a corresponding calibration line located within the boundaries of the vali- dation window 29 is illustrated in Fig. 10; see literals 25b to 27b and 30.
Even more powerful is the validation of results by means of statistical evaluation and linear regression analysis. The quality of the calibration can be judged by a correlation coeffi- cient ¢* and a confidence interval, thus the analyte test system can refuse to display a meas- urement result if the correlation coefficient falls below a pre-programmed threshold. Alterna- tively, the processing means can calculate a tolerance or concentration range of the result based on the calculated confidence interval. These methods allow a high control over the quality of results provided to the patient, which is used and known today only from sophisti- cate and expensive laboratory methods and equipment. Even more important for the pa- tient/user is, especially in hospital settings, the quality assurance right at the time of the measurement.
Further security is possible in another embodiment of the present invention; here the analyte test system is configured to relate the concentration of an inert dye to the amount of the calibration compound used in the calibration step. The calibration formulation is com- posed of the calibration compound and the inert dye with a preset and fixed ratio to each other before it is dosed on the predetermined detection areas of the analyte test element.
Thus, the processing means of the analyte test system has the ability to trace and correct for slight variations in the deposited amount of calibration compound if the detector means is configured to determine the concentration of the inert dye with a wave-length different from the wave length used to evaluate the reaction of the indicator compound with the analyte.
Moreover, the manufacturing process control of the dosing and coating step of the calibration formulation become traceable and therefore more reliable. Said inert dye is pref- erably a water-soluble dye selected from the group consisting of brilliant blue G; brilliant black BN; new coccine; tartrazine; indigo carmine; sunset yellow, carmoisine; ponceau 4R; direct blue 2B; and/or a water soluble derivate of malachite green.
Due to the integrated calibration procedure and validation method, the analyte test system of the present invention provides reliable results by compensating endogenous inter- ferences, such as different blood types and haematocrit levels, as well 1s exogenous interfer- ences, such as nutrition supplements like Vitamin C or pharmaceuticals, which otherwise would influence and modify the measuring results. Since the calibration of the analyte test system is done in parallel to the measurements, different environmental parameters, such as temperature at the time of actual measurement, are of no consequence for the accuracy of the determined results.
In addition, production variations, e. g. variations in the thickness of the centre layer, are compensated by the integrated calibration procedure and active component aging, e. g., loss of enzyme activity, is traceable and may be compensated which leads then to a prolonged shelf live of the product.
Fig. 11 illustrates different embodiments and shapes of analyte test strips of the present invention adapted to different analyte test systems.
Fig. 12 shows the insertion of the analyte test strip into an analyte test system. In a pre- ferred embodiment the analyte test strip is designed to have a lateral and concave extension 10 located on one major side of the test strip where the sample application area 9 resides.
This feature allows easy application of capillary blood samples from the patients arm or finger as shown in Fig. 13.
In another embodiment of the present invention, as shown in Fig. 14, a plurality of analyte test elements is arranged symmetrically around a centre point to form an analyte test "5 disk 31 with outward facing sample application areas 39. The exemplary analyte test disk 31 according to Fig, 14a includes nine analyte test elements of the present invention. As shown in the exploded view of Fig. 14b, the analyte test disk 31 is covered by a disk cover composed of a top layer 32 and a bottom layer 33, The disk covet bottom layer 33 may also be provided with a moisture-absorbing layer 34. The top layer 32 and bottom layer 33 of the disk cover have breakthroughs which ate arranged congruently to each other, forming an optical window 35 in which the analyte test element used for the current measurement procedure is located.
Adjacent to the optical window 35 in the outer peripheral areas of the disk cover top layer 32 and the disk cover bottom layer 33 there are provided notches 36 to expose the sam- ple application area 39 of the measurement cell. Preferably, the test disk 31 is additionally provided with a registration notch 38 which may be located in the interior edge of the disk 31.
During a measurement procedure, only the analyte test element, which is currently used for the analyte determination is exposed by the optical window, as shown in Fig. 14c. The analyte test disk 31 is able to rotate around its centre point to bring a new analyte test elemeat into position as required. 20. By means of an analyte test disk, it is possible to arrange a plurality of analyte test ele- ments in a relatively small area. The same number of analyte test elements included in analyte test strips would require a much latger area and thus much more material, as illustrated by the size compatison of analyte test disk and analyte test strips illustrated in Fig. 15. Whereas the unit area 40 of the analyte test disk 31 includes nine analyte test elements 41, the same area 42 would accommodate only three analyte test strips. However, a reduction of the test strip sizes is not possible, because the handling of smaller strips would become difficult and more im- practical for the patient.
Fig. 16a and Fig. 16b show the analyte test disk included in a meter, whereby the sam- ple application area 39, 43b again protrudes from the meter housing.
Not only for the analyte test strips but also for the analyte test disk it is possible to a- dapt the measurement device (analyte test system) to a left hand and right hand handling mode as illustrated in Fig. 17. When a left hand handling mode is desired according to Fig.
17a, the analyte test strip 57 is inserted into the meter from the bottom side, the sample appli cation area 43a for receiving the physiological fluid protruding from the meter housing 58.
After completion of the measurement, the analyte concentration is presented on the analyte test system display 54. Likewise, a right hand handling mode according to Fig. 17b can be realized by adapting the display 54 of the analyte test system 59 to a converse mode of opera- tion by rotating the displayed content on the display by 180°, enabling the insertion of the analyte test strip 57 into the meter from the top side.
Fig. 18 illustrates another possibility to arrange the analyte test elements in a space- saving manner. In this embodiment the analyte test elements are arranged side by side to form a bandolier 44 with a lateral extension to form the sample application areas 9. In the bandolier, the area between two analyte test elements is provided with a perforation or break line 46 to separate a used analyte test element 45 from the unused part of the analyte test bandolier 44. By means of a zigzag-folding along the perforation or break lines 46 it is possi- ble to build an analyte test device bandolier stack 48 which can easily housed in a small con- tainer to allow an easier dispensing of the single analyte test elements of the analyte test ban- dolier.
The analyte test element of the present invention, produced in disk or strip form, can easily be prepared by processes to those of ordinary skill in the arts of printing, die punching, and laminating. The design of the analyte test element allows a simple and cost efficient pro- duction process, which is preferably but not necessarily of a continuous nature.
In a first step of the preparation method, a pattern of the sample distribution system is formed by creating areas of high and low sutface energy on a substrate. In a preferred em- bodiment, the areas of high surface energy forming the sample pathways and detection areas on the first and second surfaces are created by applying a hydrophilic formulation on a hy- drophobic surface of a substrate. As detailed above, it is also possible to create the areas of high and low surface enetgy by applying a pattern of hydrophobic “guiding elements” on a hydrophilic surface. In case the substrate has an intermediate hydrophobic character, the printing of hydrophilic pathways with surrounding hydrophobic pattem is possible as well
The substrate may be formed of a material like glass, polyvinyl acetate, poly-methyl- methacrylate, poly-dimethyl-siloxane, polyesters and polyester resins containing fluorene tings, polycarbonates and polycatbonate-polystyrene graft copolymers, terminal modified polycarbonates, polyolefins, cycloolefins and cycloolefin copolymers, and/or olefin- maleimide copolymers.
The application of a hydrophilic pattern on a hydrophobic substrate and/or the appli- cation of hydrophobic “guiding elements” on a hydrophilic substrate is preferably accom- plished with a flexography- or lithography printing process.
The flexography allows high-resolution printing on a rotary press and supports high- speed production. It is an established technology for printing on polymer film substrates and widely used in the packaging industry. The optical detection process shown in Figure 8 re- quires transparent and clear ink with low viscosity for the hydrophilic pattern. Low viscous inks are preferred to achieve a thin and even coating of about 2 - 4 mictons. The optical win- dow of the ink needs to be in the wavelength range where the indicator dye absorbs the light after the chemical reaction. The requirements for hydrophobic inks, apart from the hydro- phobic nature, ate less stringed and could be used to decorate the analyte test strip or disk with a desired colour as well The operation of a four-colour flexogmphy-printing machine is established practice and provides no operational problems. The same holds for lithography device.
Even though solvent based or UV curing inks are applicable to prepare the analyte test element, electron beam (EB) curing inks are much preferred. These inks provide highest resistance to mechanical and chemical factors, and contain 100% polymers, optionally with pigments, but no volatile organic solvents and photo initiators, which have proven to affect the stability of sensor chemistry. These positive gains in performance characteristics are de- rived from the ability of electrons to form cross-linked polymeric films and to penetrate the surface.
Inks used in EB curing make use of the polymerising capability of acrylic monomers and oligomers. Acrylic chemistry has a special significance in modem day inks. (6 J.T. Kun- jappu. “The Emergence of Polyactylates in Ink Chemistry,” Ink World, February, 1999, p. 40.) The structure of the simplest acrylic compound, acrylic acid, is shown in the formula (I)
CH,=CH-COOH ® :
The double bond in the acrylic moiety opens up during interaction with electrons (ini- tiation) and forms a free radical that acts on other monomers forming a chain (propagation) leading to high-molecular-weight polymers. As mentioned before, radiation induced polym- etisation requires no external initiator since radiation itself generates free radicals with the result that no initiating species will be left in the coating.
A variety of acrylic monomers are available for EB cuting that range from simple acrylates such as 2-phenoxyethyl acrylate and isooctyl acrylate, to pre-polymers like bisphenol
A, epoxy acrylate and polyester/polyether acrylates (R. Golden. J. Coatings Technol, 69 (1997), p. 83). This curing technology allows the design of “functional inks” with the focus on the desired chemical and physical properties without the necessity of a solvent and curing systems required by other inks, which may complicate the design process.
Suitable hydrophobic inks will contain monomers, oligomers, and prepolymers with hydrophobic functions like isooctyl acrylates, dodecyl acrylates, styrene derivates or systems with partly fluorinated carbon chains.
Inks with hydrophilic functions can be realised from a wide selection of cross-linkable water-soluble polymers, useful are acrylate derivatives prepared form polyalcohols, polyethyl- ene-glycols, polyethylene-oxides, vinylpyrolidone, alkyl-phosphocholine derivates and others; . particularly useful are organo-modified silicone acrylates, which are a cross-linkable species of organo-modified polysiloxanes. Suitable coatings provide a contact angle with water of typi- cally less than 25° and a surface energy of typically more than 70 mN/m.
The second step of the production process comprises the application of the catalytic formulation, containing an enzyme or another compound undergoing a catalytic or non- catalytic reaction with the analyte and, if necessary a co-enzyme, and an indicator dye, onto the predetermined detection areas of the sample distribution system formed on the substrate providing the first surface, and the application of calibration formulations containing different levels of calibration compound or analyte to the predetermined detection areas of the sample distribution system formed on the substrate providing the second surface.
The accuracy of this deposition step is very critical and defines the precision and per- formance of the analyte test element. Preferably, both formulations are applied with aid of high precision ink-jet systems or piezoelectric print heads. The catalytic and calibration for- mulations must be prepared to be highly soluble by the physiological fluid sample. Preferably, they are water based. Thus, these inks are mostly composed from water, enzymes, indicators,
or calibration compound respectively, and will be dried at slightly elevated temperatures. Main aspect of these ink formulations is the fast reconstitution of chemical components after sam- ple application without compromising the hydrophobic areas of the analyte test element.
The next step comprises the lamination procedure, in which the base and cover layer 5S presenting the first and second surfaces of the sample distribution system are laminated onto a ceatre layer, thereby defining a distance between the first and second surface of the base and cover layer. The centre layer provides a discontinuity to create a cavity for the sample distribution system in the areas where the sample distribution system is formed on the first and second surface of the base and cover layer. The patterns of high and low surface energy formed on the first and second surface of the base and cover layer must be aligned to be mostly congruent to enable the formation of a functional sample distribution system between the first and second surface.
Precise xy-registration of base and cover layers becomes a critical task for the function of the device, if this registration is not achieved, the sample distribution system will not func- tion propedy. Registration tolemances should be within +/- 5% of the width of the hydro- philic pathways to achieve good petformance. The application of the centre layer, which may be a double-sided adhesive tape with a preferred thickness of 80 microns, is less demanding because of the relatively large discontinuity in the matetial compared to the size of the hydro- philic pathways. Registration is especially important in continuous production lines where the substrate progresses with several meters up to tens of meters per minute. Substrate expansion and web tension make the registration in x-direction (the direction of the web movement) more difficult than the y-direction perpendicular to the web movement.
An inventive preparation method for flexible polymer films providing an accurate registration of the patterns of first and second surface is illustrated in Fig. 19 showing parts of a continuous web production process. In a first production step according to Fig. 19a, pat- terns of the sample distribution system 6 of the base and cover layer are printed on one web substrate 49, which represents the material of the analyte test element and strip, respectively.
As illustrated in Fig. 19, the printed patterns of the sample distribution systems 6 are arranged on the web substrates 49 in such a manner that two sample distribution systems are opposite to each other and linked in the areas which form later the sample application areas. Thus, the position of the predetermined detection areas 6a, 6’ is fixed relative to each other and re- mains unaffected by the material expansion and web tension.
The dotted lines 50 indicate the future cutting lines to segregate the analyte test strips, while the dotted lines 51 indicate the future fold line of the web substrate.
After printing the sample distribution areas, the detection areas 6a, 6’a of the sample distribution system ate coated with the catalytic and calibration formulations. For example, the detection areas 6'a of the lower row of the web substrate 49, which will represent the first surface of the analyte test element, are coated with the catalytic formulation containing the enzyme and an indicator, whereas the detection areas 6a of the upper row of the web sub- strate 49, which will represent the second surface of the analyte test element, are coated with calibration formulations containing different levels of the calibmtion compound; one of the calibration formulation (e. g. positioned in 6a,) does not contain calibration compound and delivers the reading of the physiological fluid in the detection step.
Thereafter, an additionally layer is laminated on one of the surfaces, e. g. the surface 2a of the base layer 2, representing the centre layer 52 of the analyte test clement as shown in _ Fig. 19b. The ceatre layer 52 may be formed of double-sided adhesive tape, which provides breakthroughs 5 exposing the sample distribution systems 6 and will create a cavity for the sample distribution systems in the analyte test element after the final assembly step.
The analyte test element of the present invention is than assembled by folding the two row sides along the fold line 51, e. g. with help of a folding iron, as illustrated in Fig. 19c cre- ating a folded and laminated web 53 as shown in Fig. 19d. Subsequently, a press roller can secure a tight connection between the centre layer, base and cover layers.
Finally, the laminated web 53 is cutted or punched in to the: desired product shape, whereas line 50 projects an exemplary shape of the final analyte test strip onto the web 53 before the segregation process. With the preparation method illustrated in Fig. 19 the top part of the substrate can be folded on to the bottom part without the danger of loosing the regis- tration in the x-direction of the web and provides an easier method to get the right registra- tion of the first and second surfaces forming the sample distribution system in comparison to single sheet process.
The present invention provides an analyte test system that incorporates calibration and quality control means in a dry reagent test strip format that does not make excessive de- mand on the strip production process but eliminates the need for user interveations in cali- .bration and quality control procedures in combination with a tight control of the strip per- formance at time of sample analysis.
Claims (37)
1. An analyte test element for determining the concentration of at least one analyteina physiological sample fluid having a first surface and a second surface in a predeter- mined distance opposite from each other, said both surfaces are provided with two substan- tially ‘equivalent patterns forming areas of high and low surface energy which are aligned mostly congruent to create a sample distribution system _ with at least two detection areas, wherein the applied physiological fluid is constrained to the areas with high surface en- ergy-
2. The analyte test element according to claim 1, wherein the distance between the first and second surface is determined by a centre layer ~~ which is arranged between a base layer and a cover layer having the first and second surfaces,
3. The analyte test element according to claim 2, wherein the centre layer has a dis- continuity to form a hollow cavity together with the first and second surface of the base and cover layer said hollow cavity being larger than the sample distribution system formed by the areas of high surface energy on the first and second surfaces
4. The analyte test element according to one of the preceding claims, wherein said ar- eas of high surface energy are created by applying cross-linkable and/or non-soluble hydro- philic and/or amphiphilic agents on the first and second surfaces,
5. The analyte test element according to claim 4, wherein said hydrophilic agents are selected from the group consisting of functionalised derivates from polyalcohols, polyethyl- ene-glycols, polyethylene-oxides, vinylpyrrolidones and ofgano-modified polysiloxanes or alkyl-phosphocholine polyethylene-glycol copolymers.
6. The analyte test element according to one of the preceding claims, wherein said first surface. and second surface are hydrophobic and non-wettable by a physiological AMENDED SHEET 2007 -03- 13 fluid and transparent for light particular in the UV, near IR and/or visible range of the elec- tromagnetic spectrum.
: 7. The analyte test element according to one of the preceding claims, wherein said ar- eas of low surface energy ate created by applying a hydrophobic composition on the first and second surfaces; said hydrophobic composition preventing the wetting of the coated area by a physiological fluid.
8. The analyte test element according to claim 7, wherein said hydrophobic composi- tion contains isooctyl acrylates, dodecyl acrylates, styrene derivates, or systems with partly fluorinated carbon chains.
9. The analyte test element according to claim 7, wherein said first surface and se- cond surfaces are hydrophilic and wettable for the physiological fluid and transparent for light particular in the UV, near IR and/or visible range of the electromagnetic spectrum.
10. The analyte test element according to claim 9, wherein said first surface and second surface are rendered hydrophilic by physical or chemical vapour deposition of hydrophilic compounds.
11. The analyte test element according to one of the preceding claims, wherein the ba- se layer and cover layer providing the first and second surfaces are formed of a material selected from the group consisting of glass, polyvinyl acetate, poly-methyl- methacrylate, poly-dimethyl-siloxane, polyesters and polyester resins containing fluorene rnngs, polycarbonates and polycarbonate-polystyrene graft copolymers, terminal modified polycarbonates, polyolefins, cycloolefins and cycloolefin copolymers, and/or olefin- maleimide copolymers.
12. The analyte test element according to one of the preceding claims, wherein n predetermined detection areas of said first surface are coated with a catalytic formulation promoting the detection of an analyte in a physiological fluid, and 5-13 AMENDED SHEET 2007 -0 n predetermined detection areas of said second surface are coated with # cali- bration formulations made up of 7 blank formulations and 7-7 formulations with different levels of calibration compound, whereby # is an integer number larger than 2, 7 is an integer number equal or larger than 1, and 7 >. :
13. The analyte test element according to claim 12, wherein an additionally detection area is provided which neither contains the catalytic compound nor the calibration com- pound, enabling the measurement of background signals.
14. The analyte test element according to claim 12 or claim 13, wherein said catalytic + formulation coated on # predetermined detection areas of first surface allows the detection of an analyte concentration contained in a physiological fluid sample using trans- mission or absorbance photometry.
15. The analyte test element according to claim 12, wherein said calibration com- pound contained in the calibration formulation coated on #-m predetermined detection areas of second surface is identical or substantially equivalent to the analyte and able to induce the same chemical reaction in the catalytic formulation as the analyte in the physio- logical fluid sample.
16. The analyte test element according to claim 15, wherein the calibration compound is glucose.
17. The analyte test element according to claim 12, wherein the catalytic formulation contains as reactive components a promoter undergoing a catalytic or non-catalytic reaction with the analyte, and/or a co-enzyme, and an indicator generating an optically detectable product.
18. The analyte test element according to claim 17, wherein the promoter is an en- zyme selected from the group consisting of dehydrogenases, kinases, oxidases, phosphatases, reductases and/or transferases. AMENDED SHEET 2007 -05- 13
19. The analyte test element according to claim 18, wherein the promoter is an en- _ zyme specific for glucose.
20. The analyte test element according to claim 17, wherein the indicator to determine the analyte concentration is selected from the group consisting of aromatic amines, aromatic -alcohols, azines, benzidines, hydrazones, aminoantipyrines, conjugated amines, conjugated alcohols, and/or aromatic and aliphatic aldehydes.
21. The analyte test element according to at least one of claims 12 to 20, wherein the calibration formulation applied to the predetermined detection areas of second surface contains an inert water-soluble dye in a predetermined and fixed ratio to the calibration compound allowing a suitable reading device to evaluate the concentration of the calibration compound within the calibration formulation with 2 wave length different from the wave length used to measure the reaction product of the catalytic formulation with the analyte.
22. The analyte test element according to claim 21, wherein said inert wates-soluble dye is selected from the group consisting of brilliant blue G; brilliant black BN; new coccine; tartrazine; indigo carmine; sunset yellow, carmoisine; ponceau 4R; direct blue 2B; and/or a water soluble derivate of malachite green.
23. The analyte test element according to one of the preceding claims, wherein a sam- ple application area is located at the end of a convex and lateral extension on one side of said analyte test element.
24. An analyte test arrangement including a plurality of devices according to one of the preceding claims, which are arranged symmetrically around a centre point to form an analyte testdisk with outward facing sample application areas,
25. An analyte test arrangement including a plurality of devices according to at least one of the preceding claims, which are arranged in a linear manner to form an analyte test bando- lier with lateral extensions forming the sample application areas. AMENDED SHEET 2007 -03- 13
26. A method for preparing an analyte test element comprising the steps: applying areas of high and low surface energy on a base layer having a first surface, the areas of high surface energy forming a hydrophilic path with # predetermined detec- tion areas, whereby 7 is an integer number equal or larger than 2, applying a corresponding pattern of areas of high and low surface energy on a cover layer having a second surface, coating a catalytic formulation on the # detection areas of the first surface, said catalytic formulation promoting the detection of an analyte concentration contained in a physiological fluid sample using transmission or absorbance photometry, coating # calibration formulations on » detection areas of the second surface, said # calibration formulations made up of # blank formulations and #-m formulations with different levels of calibration compound, whereby is an integer number of at least 1, and n>m, which is identical or substantially equivalent to the analyte and able to induce the same chemical reaction in the catalytic formulation as the analyte in the physiological fluid sample, laminating the layers of first and second surfaces to the opposite sites of a centre layer having a discontinuity ~~ which provides a cavity for the sample distribution system formed by the areas of high surface energy on the first and second surfaces of the base and cover layer, punching or cutting the laminated sheets to the final shape.
27. A method for preparing an analyte test element according to claim 26, wherein said areas of high surface energy are created by applying cross-linkable and/or non-soluble hydro- philic and/or amphiphilic agents on the first and second surfaces, said hydrophilic and/or amphiphilic agents.
28. A method for preparing an analyte test element according to claim 27, wherein said areas of high surface energy are printed on the first and second surface by the means of flexography or lithography.
29. A method for preparing an analyte test element according to one of claims 26 to 28, wherein said areas of low surface energy are created by applying a hydrophobic com- AMENDED SHEET 2007 -03- 13 pound on the first and second surfaces, said hydrophobic compound preventing the wetting of the coated area by a physiological fluid.
30. A method for preparing an analyte test element according to claim 29, wherein said first and second surfaces are rendered hydrophilic by physical or chemical vapour deposition of hydrophilic compounds.
31. A method for preparing an analyte test element according to one of claims 26 to 30, wherein the areas of high sutface energy of first and second surfaces are physically elevated from the areas of low surface energy by etching or embossing.
32. A method for preparing an analyte test element according to one of claims 29 to 31, wherein said areas of low surface energy are printed on the first and second surface by the means of flexography or lithography.
33. A method for preparing an analyte test element according to one of claims 26 to 32, wherein the base layer and the cover layer are formed from one flexible substrate and folded along a longitudinal centred fold line to enclose the centre layer in a manner that the sample distribution system with the predetermined detection areas of said first surface and second surface are aligned and registered to be mostly congruent.
34. An analyte test system for determining the concentration of an analyte in a physio- logical sample fluid comprising an analyte test element or analyte test arrangement according to one of claims 1 to 25, wherein 7 predetermined detection areas of a first surface are coated with a catalytic formulation promoting the detection of an analyte in a physiological fluid, and n predetermined detection areas of a second surface are coated with » calibra- tion formulations made up of blank formulations and 7-7 formulations with different lev- els of calibration compound, whereby is an integer number larger than 2, is an integer number equal or larger than 1, and # >, OMENDED SHEET 2007-03-13 detection means for detecting changes of light absorbance of the physiological sample located in 2n predetermined detection areas and obtaining # results from 27 predetermined detection areas, and : processing means for calculating #- calibration coefficients of a polynomial calibration equation obeying n-1 » 7 = {nx},
1 . 10 and one regression coefficient to validate the quality of the calculated 7-7 calibration coeffi dents of the calibration equation.
35. A method for determining the concentration of at least one analyte in a physio- logical sample, said method comprising applying a physiological sample to an analyte test element having a first surface ~~ and a second surface in a predetermined distance opposite from each other, said both sur- faces are provided with two substantially equivalent patterns forming areas of high and low surface energy which are aligned mostly congruent to create a sample distribution system with at least two detection areas, wherein the applied physiological fluid is constrained to the areas with high surface energy, detecting the signals produced in the different detection areas, and relating the signals to determine the amount of the analyte(s) in the physiological sam-
ple.
36. An analyte test element for determining the concentration of at least one analyte in physiological sample fluid, substantially as herein described and illustrated.
37. A method for preparing an analyte test element, substantially as herein described. AMENDED SHEET 3g07 -09- 13
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200606458A ZA200606458B (en) | 2004-03-05 | 2004-03-05 | Analyte test system for determining the concentration of an analyte in a physiological fluid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200606458A ZA200606458B (en) | 2004-03-05 | 2004-03-05 | Analyte test system for determining the concentration of an analyte in a physiological fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200606458B true ZA200606458B (en) | 2008-01-30 |
Family
ID=40635418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200606458A ZA200606458B (en) | 2004-03-05 | 2004-03-05 | Analyte test system for determining the concentration of an analyte in a physiological fluid |
Country Status (1)
| Country | Link |
|---|---|
| ZA (1) | ZA200606458B (en) |
-
2004
- 2004-03-05 ZA ZA200606458A patent/ZA200606458B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1723412B1 (en) | Analyte test system for determining the concentration of an analyte in a physiological fluid | |
| EP1776464B1 (en) | Analyte test system for determining the concentration of an analyte in a physiological or aqueous fluid | |
| US6511814B1 (en) | Method and device for detecting analytes in fluids | |
| US5597532A (en) | Apparatus for determining substances contained in a body fluid | |
| US6312888B1 (en) | Diagnostic assay for a sample of biological fluid | |
| KR100884501B1 (en) | Immunosensor | |
| US20030207441A1 (en) | Devices and methods for analyte concentration determination | |
| US20030068666A1 (en) | Dual glucose-hydroxybutyrate analytical sensors | |
| US20090075389A1 (en) | Method for determining an analyte in a fluid | |
| KR20080088028A (en) | Electrochemical biosensor and measuring instrument thereof | |
| KR100854389B1 (en) | Electrochemical biosensor | |
| EP1298437B1 (en) | Colorimetric test device with reduced error | |
| ZA200606458B (en) | Analyte test system for determining the concentration of an analyte in a physiological fluid | |
| WO2000078998A1 (en) | Apparatus and method for determining substances contained in a body fluid | |
| KR20220064861A (en) | Systems and Methods for Measuring Liver Enzyme Levels in Blood | |
| KR20070002042A (en) | Analyte test system for determining the concentration of an analyte in a physiological fluid | |
| MXPA06010066A (en) | Analyte test system for determining the concentration of an analyte in a physiological fluid | |
| KR20070073746A (en) | Analyte test system for determining the concentration of an analyte in a physiological or aqueous fluid |